CELZ
NASDAQ · Biotechnology
Creative Medical Technology
$1.94
-0.03 (-1.52%)
Financial Highlights (FY 2026)
Revenue
28.1K
Net Income
-14,072,972
Gross Margin
60.0%
Profit Margin
-49,940.7%
Rev Growth
-50.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 60.0% | 60.0% | 46.2% | 46.2% |
| Operating Margin | -52,216.9% | -46,995.6% | -15.1% | -16.5% |
| Profit Margin | -49,940.7% | -47,443.7% | -20.6% | -17.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 28.1K | 56.5K | 749.0K | 753.7K |
| Gross Profit | 16.8K | 33.9K | 346.3K | 348.5K |
| Operating Income | -14,654,153 | -26,574,123 | -113,316 | -124,382 |
| Net Income | -14,072,972 | -25,520,199 | -154,552 | -129,649 |
| Gross Margin | 60.0% | 60.0% | 46.2% | 46.2% |
| Operating Margin | -52,216.9% | -46,995.6% | -15.1% | -16.5% |
| Profit Margin | -49,940.7% | -47,443.7% | -20.6% | -17.2% |
| Rev Growth | -50.4% | -50.4% | +1.8% | -1.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 572.6K | 615.2K |
| Total Equity | — | — | 3.37M | 3.00M |
| D/E Ratio | — | — | 0.17 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -14,431,357 | -27,623,995 | -155,667 | -163,320 |
| Free Cash Flow | — | — | -141,548 | -126,501 |